Royalty Pharma plc (RPRX) Institutional Holders & Insider Trades

Royalty Pharma plc

RPRX · Nasdaq

Symbol: RPRX
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: Nasdaq

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.

Key Issues

Bullish view

Adjusted EBITDA increased to $736 million from $633 million, while quarterly earnings and revenue exceeded estimates by 3.94% and 1.52%. That supports a view that underlying operating performance remains strong despite lower reported net income.

Bearish view

Net income attributable to Royalty Pharma declined to $18 million from $32 million. Investors may therefore question whether the stronger adjusted EBITDA meaningfully translates into bottom-line earnings.

Analyst Consensus

See all

Buy

7 analysts

$60

Current

—

Low

$66

Average

—

High

Average target implies +10.78% versus the current price.

Earnings History

BeatMissNo estimate

Royalty Pharma plc

Peers